Zhejiang Hisun Pharmaceutical Co Ltd (600267) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Zhejiang Hisun Pharmaceutical Co Ltd (600267) has a cash flow conversion efficiency ratio of 0.050x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥438.43 Million ≈ $64.16 Million USD) by net assets (CN¥8.76 Billion ≈ $1.28 Billion USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Zhejiang Hisun Pharmaceutical Co Ltd market cap and net worth for the company's overall valuation and market capitalisation.
Zhejiang Hisun Pharmaceutical Co Ltd - Cash Flow Conversion Efficiency Trend (1999–2025)
This chart illustrates how Zhejiang Hisun Pharmaceutical Co Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Zhejiang Hisun Pharmaceutical Co Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Zhejiang Hisun Pharmaceutical Co Ltd ranked by their cash flow conversion efficiency. Explore 600267 operating cash flow to net income to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Domain Holdings Australia Ltd
AU:DHG
|
0.049x |
|
Malaysian Pacific Industries
KLSE:3867
|
0.040x |
|
Central China Securities Co Ltd
SHG:601375
|
0.335x |
|
BWP Trust
AU:BWP
|
0.020x |
|
King’s Town Bank
TW:2809
|
0.025x |
|
China Automotive Engineering Research Institute Co Ltd
SHG:601965
|
0.016x |
|
Resolute Mining Ltd
AU:RSG
|
0.174x |
|
AVI LTD (UNSP.ADR)/5
F:IZ60
|
N/A |
Annual Cash Flow Conversion Efficiency for Zhejiang Hisun Pharmaceutical Co Ltd (1999–2025)
The table below shows the annual cash flow conversion efficiency of Zhejiang Hisun Pharmaceutical Co Ltd from 1999 to 2025. View latest Zhejiang Hisun Pharmaceutical Co Ltd stock price today for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | CN¥8.85 Billion ≈ $1.30 Billion |
CN¥2.03 Billion ≈ $297.30 Million |
0.230x | -6.88% |
| 2024-12-31 | CN¥8.58 Billion ≈ $1.26 Billion |
CN¥2.11 Billion ≈ $309.42 Million |
0.246x | +35.66% |
| 2023-12-31 | CN¥8.35 Billion ≈ $1.22 Billion |
CN¥1.52 Billion ≈ $221.98 Million |
0.182x | -26.73% |
| 2022-12-31 | CN¥8.33 Billion ≈ $1.22 Billion |
CN¥2.07 Billion ≈ $302.28 Million |
0.248x | +4.90% |
| 2021-12-31 | CN¥7.35 Billion ≈ $1.07 Billion |
CN¥1.74 Billion ≈ $254.11 Million |
0.236x | +22.79% |
| 2020-12-31 | CN¥8.26 Billion ≈ $1.21 Billion |
CN¥1.59 Billion ≈ $232.61 Million |
0.193x | +111.79% |
| 2019-12-31 | CN¥7.68 Billion ≈ $1.12 Billion |
CN¥698.39 Million ≈ $102.20 Million |
0.091x | -53.62% |
| 2018-12-31 | CN¥7.38 Billion ≈ $1.08 Billion |
CN¥1.45 Billion ≈ $211.64 Million |
0.196x | +24.42% |
| 2017-12-31 | CN¥7.88 Billion ≈ $1.15 Billion |
CN¥1.24 Billion ≈ $181.55 Million |
0.158x | +63.23% |
| 2016-12-31 | CN¥8.04 Billion ≈ $1.18 Billion |
CN¥775.90 Million ≈ $113.54 Million |
0.097x | +7.05% |
| 2015-12-31 | CN¥8.17 Billion ≈ $1.19 Billion |
CN¥736.17 Million ≈ $107.72 Million |
0.090x | +30.49% |
| 2014-12-31 | CN¥8.26 Billion ≈ $1.21 Billion |
CN¥571.04 Million ≈ $83.56 Million |
0.069x | -21.92% |
| 2013-12-31 | CN¥5.96 Billion ≈ $871.87 Million |
CN¥527.25 Million ≈ $77.15 Million |
0.088x | +22.41% |
| 2012-12-31 | CN¥5.20 Billion ≈ $760.59 Million |
CN¥375.75 Million ≈ $54.98 Million |
0.072x | -36.79% |
| 2011-12-31 | CN¥4.59 Billion ≈ $672.18 Million |
CN¥525.31 Million ≈ $76.87 Million |
0.114x | -38.37% |
| 2010-12-31 | CN¥2.74 Billion ≈ $401.57 Million |
CN¥509.18 Million ≈ $74.51 Million |
0.186x | -4.62% |
| 2009-12-31 | CN¥2.43 Billion ≈ $355.67 Million |
CN¥472.85 Million ≈ $69.19 Million |
0.195x | +36.20% |
| 2008-12-31 | CN¥1.55 Billion ≈ $226.70 Million |
CN¥221.28 Million ≈ $32.38 Million |
0.143x | -55.07% |
| 2007-12-31 | CN¥1.38 Billion ≈ $201.50 Million |
CN¥437.72 Million ≈ $64.05 Million |
0.318x | +273.86% |
| 2006-12-31 | CN¥1.27 Billion ≈ $185.92 Million |
CN¥108.03 Million ≈ $15.81 Million |
0.085x | -8.03% |
| 2005-12-31 | CN¥1.23 Billion ≈ $179.69 Million |
CN¥113.53 Million ≈ $16.61 Million |
0.092x | -64.49% |
| 2004-12-31 | CN¥1.20 Billion ≈ $175.90 Million |
CN¥312.93 Million ≈ $45.79 Million |
0.260x | -9.59% |
| 2003-12-31 | CN¥1.00 Billion ≈ $146.59 Million |
CN¥288.45 Million ≈ $42.21 Million |
0.288x | +96.58% |
| 2002-12-31 | CN¥824.83 Million ≈ $120.70 Million |
CN¥120.82 Million ≈ $17.68 Million |
0.146x | +66.14% |
| 2001-12-31 | CN¥784.18 Million ≈ $114.75 Million |
CN¥69.14 Million ≈ $10.12 Million |
0.088x | +19.97% |
| 2000-12-31 | CN¥757.90 Million ≈ $110.90 Million |
CN¥55.70 Million ≈ $8.15 Million |
0.073x | -43.75% |
| 1999-12-31 | CN¥249.88 Million ≈ $36.56 Million |
CN¥32.64 Million ≈ $4.78 Million |
0.131x | -- |
About Zhejiang Hisun Pharmaceutical Co Ltd
Zhejiang Hisun Pharmaceutical Co., Ltd. engages in the research, development, production, and sale of biological and generic drugs in China. The company provides active pharmaceutical ingredients. It also offers its products for anti-tumor, anti-infection, cardiovascular, endocrine, immunosuppression, antidepressant, and orthopedics treatment; nutrition and healthcare; and oncology, ADC small mol… Read more